Search
forResearch 10 of 1000+
- Pathogenesis of Hand-Foot Syndrome induced by PEG-modified liposomal Doxorubicin
- High incidence of severe hand–foot syndrome during capecitabine–docetaxel combination chemotherapy
- Hand-Foot and Stump Syndrome to Sorafenib
- Cutaneous toxicities of cancer therapy
- Pegylated Liposomal Doxorubicin in the Treatment of Breast Cancer
- Doxil (Caelyx): an exploratory study with pharmacokinetics in patients with hormone-refractory prostate cancer
- Clinical development and management of adverse events associated with FGFR inhibitors
- Cutaneous Reactions to Chemotherapeutic Agents
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Management of adverse events and other practical considerations in patients receiving capecitabine (Xeloda®)
Learn
— no results
Try a deeper search in learn →Community
— no results
Try a deeper search in community →